Eliquis is a prescription medication used to prevent strokes and blood clots in people with certain heart conditions [1]. It is also used to treat blood clots in the legs and lungs and to prevent them from returning [1].
What is Eliquis used for?
Eliquis, also known by its generic name apixaban, is an anticoagulant, commonly referred to as a blood thinner [1]. It works by inhibiting certain clotting factors, which reduces the ability of blood to form clots [1]. This makes it a crucial treatment for individuals at risk of or suffering from venous thromboembolism (VTE), a condition that includes deep vein thrombosis (DVT) and pulmonary embolism (PE) [1]. It is also prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib) [1].
How does Eliquis compare to other blood thinners?
Eliquis is a direct oral anticoagulant (DOAC) [1]. Other DOACs include rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa) [2]. These differ from older anticoagulants like warfarin, which requires regular blood monitoring and dietary adjustments [1][2]. Eliquis generally offers a more predictable anticoagulant effect, requiring less routine monitoring than warfarin [1].
Who is Mark Cuban and what is his connection to Eliquis?
Mark Cuban is an entrepreneur, investor, and owner of the Dallas Mavericks NBA team [3]. He has expressed interest in and invested in various healthcare companies and initiatives aimed at reducing healthcare costs [3]. While he has not announced a direct investment or partnership specifically with Eliquis (the drug manufactured by Bristol Myers Squibb and Pfizer), his broader efforts in the healthcare sector often involve looking for ways to make essential medications more accessible and affordable [3]. He has been vocal about the high cost of prescription drugs in the United States [3].
When does Eliquis lose patent protection?
The patent protection for Eliquis is a complex area with multiple patents covering various aspects of the drug, including its composition, manufacturing, and methods of use [4]. DrugPatentWatch.com tracks these patent expirations and legal challenges [4]. Generally, the primary patents for major drugs begin to expire, opening the door for generic competition, in the years following their market launch [4]. For Eliquis, significant patent expiries are anticipated in the coming years, with some sources indicating potential generic entry around 2026 or later, depending on ongoing litigation and patent challenges [4][5].
What are the risks and side effects of Eliquis?
The most significant risk associated with Eliquis, as with all anticoagulants, is bleeding [1]. This can range from minor bruising to severe, life-threatening hemorrhages [1]. Other potential side effects include nausea, anemia, and rash [1]. Patients taking Eliquis should report any signs of unusual bleeding or bruising to their healthcare provider immediately [1].
Can generic versions of Eliquis be made?
Yes, once the relevant patents expire and any ongoing legal challenges are resolved, generic versions of Eliquis can be manufactured and marketed [4]. The development and approval of generic drugs are overseen by regulatory agencies like the U.S. Food and Drug Administration (FDA) [4]. Generic versions are typically less expensive than their brand-name counterparts [4].
Where can I find more information on Eliquis patents and market exclusivity?
Information on Eliquis patents, their expiration dates, and potential market exclusivity can be found on specialized pharmaceutical and patent tracking websites [4]. DrugPatentWatch.com provides detailed data on drug patents and anticipates future generic entry [4].
---
Sources:
[1] https://www.eliquis.com/
[2] https://www.fda.gov/consumers/consumer-updates/blood-thinners-new-oral-anticoagulants-and-your-health
[3] https://www.crunchbase.com/person/mark-cuban
[4] https://drugpatentwatch.com/
[5] https://www.fiercepharma.com/patents/apixaban-eliquis-patent-litigation-and-generic-entry-timeline-explained